Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: A 26 week, randomised clinical trial (ELEGANT)

Diabetologia

Volumn 57, Issue 9, 2014, Pages 1812-1819

  De Wit, Helena M ^a   Vervoort, Gerald M M ^a   Jansen, Henry J ^a,b   De Grauw, Wim J C ^a   De Galan, Bastiaan E ^a   Tack, Cees J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

Insulin therapy; Liraglutide; Type 2 diabetes; Weight gain

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIABETIC PATIENT; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; NAUSEA AND VOMITING; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTPATIENT DEPARTMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TEACHING HOSPITAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; ACNE; DISEASE SEVERITY; FOLLOW UP; HIP CIRCUMFERENCE; MAJOR CLINICAL STUDY; NAUSEA; OBESITY; VOMITING; WAIST CIRCUMFERENCE;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; WEIGHT GAIN;

EID: 84905580879     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3302-0     Document Type: Article

References (37)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596
2. Riddle MC (2004) Timely initiation of basal insulin. Am J Med 116(Suppl 3A):3S-9S
3. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589
5. Jansen HJ, Hendriks JC, de Galan BE, Penders G, Tack CJ, Vervoort G (2011) Contribution of change in glycosylated haemoglobin to insulin-associated weight gain: results of a longitudinal study in type 2 diabetic patients. Endocrine 39:190-197
6. Jansen HJ, Vervoort G, van der Graaf M, Tack CJ (2010) Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile. Neth J Med 68:359-366
7. Holman RR, Thorne KI, Farmer AJ, et al. (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357:1716-1730
8. Salle A, Ryan M, Guilloteau G, Bouhanick B, Berrut G, Ritz P (2005) 'Glucose control-related' and 'non-glucose control-related' effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients. Br J Nutr 94:931-937
9. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S (2008) Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 14:161-168
10. Marre M, Shaw J, Brandle M, et al. (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 26:268-278
11. Nauck M, Frid A, Hermansen K, et al. (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
12. Garber A, Henry R, Ratner R, et al. (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
13. Zinman B, Gerich J, Buse JB, et al. (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224-1230
14. Russell-Jones D, Vaag A, Schmitz O, et al. (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52:2046-2055
15. Nauck MA, Kemmeries G, Holst JJ, Meier JJ (2011) Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60:1561-1565
16. Arnolds S, Dellweg S, Clair J, et al. (2010) Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33:1509-1515
17. Buse JB, Bergenstal RM, Glass LC, et al. (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154:103-112
18. Lane W, Weinrib S, Rappaport J (2011) The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther 13:592-595
19. Lane W, Weinrib S, Rappaport J, Hale C (2014) The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes Obes Metab. doi: 10.1111/dom.12286
20. Levin PA, Mersey JH, Zhou S, Bromberger LA (2012) Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 18:17-25
21. Li CJ, Li J, Zhang QM, et al. (2012) Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol 11:142
22. Lind M, Jendle J, Torffvit O, Lager I (2012) Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 6:41-46
23. Mathieu C, Rodbard HW, Cariou B, et al. (2014) A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. doi: 10.1111/dom.12262
24. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM (2010) Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 103:687-694
25. Riddle MC, Aronson R, Home P, et al. (2013) Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36:2489-2496
26. Riddle MC, Forst T, Aronson R, et al. (2013) Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 36:2497-2503
27. Seino Y, Min KW, Niemoeller E, Takami A, EG-LAS Investigators (2012) Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 14:910-917
28. Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA (2008) Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 14:285-292
29. Thong KY, Jose B, Sukumar N, et al. (2011) Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 13:703-710
30. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P (2007) Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 13:444-450
31. Yoon NM, Cavaghan MK, Brunelle RL, Roach P (2009) Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 31:1511-1523
32. Polonsky WH, Anderson BJ, Lohrer PA, et al. (1995) Assessment of diabetes-related distress. Diabetes Care 18:754-760
33. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571
34. St-Onge M, Mignault D, Allison DB, Rabasa-Lhoret R (2007) Evaluation of a portable device to measure daily energy expenditure in free-living adults. Am J Clin Nutr 85:742-749
35. Balena R, Hensley IE, Miller S, Barnett AH (2013) Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 15:485-502
36. Donnelly JE, Blair SN, Jakicic JM, et al. (2009) American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 41:459-471
37. Wing RR, Lang W, Wadden TA, et al. (2011) Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34:1481-1486